Results 1 - 10 of 242 : 1 2 3 4 5 6 7 8 9 Next
A few signals that Pfizer might be the one bidding on ImClone.
InterMune Previews a Coming Attraction
Early data on its new hepatitis C compound looks good -- for now.
The company's potential hepatitis C compound proves effective with fewer dosages.
One Share Offering Too Many for Vertex?
Vertex raises cash again by diluting itself.
Schering is cutting jobs. Maybe the government should help out?
J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
Ranbaxy's Troubles Won't Help Competitors
It may be hard to get a hit in with so much competition kicking Ranbaxy while it's down.
Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
Is Pharma Still a Safe Investment?
Judging by Monday, it doesn't seem like it. But is that really true?
Promising companies chosen by investors with a history of winning picks.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK